PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsRespiratory syncytial virus infections
MeSH D018357 - respiratory syncytial virus infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018186:Pneumovirus infections
0 Companies
0 Drugs
Success rate
D018357: 
Respiratory syncytial virus infections
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaRibavirin Ribavirin  2004-10-04   
Ribavirin Ribavirin Teva  2009-03-31   
Ribavirin Ribavirin Teva Pharma B.V  2009-07-01   
MylanRibavirin Ribavirin Mylan (previously Ribavirin Three Rivers)  2010-06-10   
RocheRibavirin Copegus  2002-12-03   
Ribavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
SandozRibavirin Ribavirin  2006-10-03   
AstraZenecaPalivizumab Synagis  1999-08-13 $226 M Q2/21-Q2/24 
Bausch Health CompaniesRibavirin Virazole  1985-12-31   
Merck & CoRibavirin Cotronak  1999-05-07   
Ribavirin, Peginterferon alfa-2b PegIntron/ Rebetol Combo Pack  2008-06-13   
Ribavirin Rebetol  1998-06-03   
Aurobindo PharmaRibavirin Ribavirin  2009-09-17   
Zydus TherapeuticsRibavirin Ribavirin  2005-12-05   
Chartwell PharmaceuticalsRibavirin Ribasphere  2004-04-06   
Ribavirin Ribavirin  2004-04-06   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
44%
4/9
Phase 2
83%
5/6
Phase 3
63%
5/8
Approved: 3Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Roche
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use